HomeABCL • NASDAQ
add
AbCellera Biologics Inc
Previous close
$2.02
Day range
$2.00 - $2.06
Year range
$1.89 - $4.34
Market cap
605.92M USD
Avg Volume
4.70M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 4.24M | -57.45% |
Operating expense | 24.40M | -4.55% |
Net income | -45.62M | -12.34% |
Net profit margin | -1.08K | -164.04% |
Earnings per share | -0.15 | -7.14% |
EBITDA | -57.33M | -14.54% |
Effective tax rate | 13.90% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 605.27M | -13.29% |
Total assets | 1.34B | -8.13% |
Total liabilities | 321.23M | -3.59% |
Total equity | 1.02B | — |
Shares outstanding | 297.69M | — |
Price to book | 0.59 | — |
Return on assets | -11.58% | — |
Return on capital | -14.19% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -45.62M | -12.34% |
Cash from operations | -11.55M | 72.30% |
Cash from investing | 7.94M | -73.47% |
Cash from financing | 5.97M | 110.88% |
Net change in cash | 2.94M | 130.17% |
Free cash flow | -58.96M | -12.73% |
About
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Founded
2012
Headquarters
Website
Employees
596
